We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Giovanna
Nalesso
g.nalesso@surrey.ac.uk
Mrs
Louise
Phillips
louise.phillips@nihr.ac.uk
Dr
Giovanna
Nalesso
g.nalesso@surrey.ac.uk
Miss
Irrum
Afzal
Irrum.afzal@nhs.net
Dr
Giovanna
Nalesso
g.nalesso@surrey.ac.uk
Arthrosis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Our overall aim is to characterise the molecular mechanisms leading to the degeneration of joint tissues in osteoarthritis (OA). OA is a cause of chronic pain and disability for millions of people worldwide. The available therapeutic options consist in symptomatic relief until surgical joint replacement becomes unavoidable. The understanding of the molecular triggers of the disease will consent us to design new drugs to promote tissue repair without the need of surgeries.
Our preliminary evidence shows that the activity of certain molecules (namely Wnts and Calcium Calmodulin Kinase 2, CaMKII) play a role in maintaining the integrity of the tissue in the joint and their activity is deregulated during OA progression. We want to understand whether by re-establishing the level of activity that these molecules had in the healthy tissue could halt disease progression.
To do so we will perform experiments on cells and pieces of tissues of the joint removed during knee or hip replacement surgeries of patients affected by OA (as a source of “diseased tissues) or who fractured their hip (as a source of “normal tissues”). We will isolate joint tissues from the “surgical waste” of the procedures. No tissue will be removed purely for research purposes.
Joint replacement surgeries will be performed by a trained orthopaedic surgeon. Limited anonymised datasets (date of birth, gender, diagnosis, presence and details of comorbidities and their pharmacological management) will be acquired. The samples will be processed in the facilities of the University of Surrey while experiments on the isolated cells will both be performed at the University of Surrey, at the William Harvey Research Institute and at the Royal Veterinary College (London), where the cells will be shipped. This research received fund by Medical Research Council and the Academy for Medical Sciences for 3 years.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Sepsis or infection of the joint to be replaced.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Giovanna
Nalesso
g.nalesso@surrey.ac.uk
Mrs
Louise
Phillips
louise.phillips@nihr.ac.uk
Miss
Irrum
Afzal
Irrum.afzal@nhs.net
Dr
Giovanna
Nalesso
g.nalesso@surrey.ac.uk
Dr
Giovanna
Nalesso
g.nalesso@surrey.ac.uk
The study is sponsored by University of Surrey and funded by Medical Research Council (MRC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 41918
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
